HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on UroGen Pharma (NASDAQ:URGN) with a maintained price target of $54.
April 18, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on UroGen Pharma with a $54 price target.
The reiteration of a Buy rating and maintenance of a $54 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement could lead to increased investor confidence in UroGen Pharma, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100